TOMI Environmental Solutions, Inc. (“TOMI”) a global decontamination and infection prevention company that specializes in disinfection/decontamination sales and services, including the manufacturing, sale and licensing of its SteraMist, a hydrogen peroxide-based mist/fog that is registered with the U.S. Environmental Protection Agency (“EPA”), announced the publication of a peer reviewed paper titled “Use of Novel Approaches to Reduce Clostridium Difficile in an Inner City Hospital,” which concluded that the use of TOMI’s SteraMist BIT contributed to the substantial reduction in a Wilmington, Delaware hospital’s Clostridium Difficile (C. Diff) burden. The paper was written by Dr. Helene Paxton, MS, MT (ASCP), PhD, CIC, Infection Preventionist, Bio Guidance, LLC and member of TOMI’s Science Advisory Board, and outlines the incorporation of SteraMist BIT into everyday disinfection protocols of a healthcare facility. This paper was peer reviewed by Dr. Uyen Nguyen.
“In the healthcare space, TOMI has been making strides to continuously demonstrate the efficacy of SteraMist in combating and reducing hospital infections,” said Dr. Halden Shane, CEO and Chairman of TOMI Environmental Solutions, Inc. “This further review and publication of the efficacy of TOMI’s SteraMist is an important verification in our battle to address the increase in C. diff infections, which lead to thousands of deaths in the U.S. each year.”
To read this article in its entirety please click on the following link:
Nearly 300 people die in the U.S. every day from an infection they acquired during their hospital stay, and the death toll is even higher internationally. Healthcare Associated Infections (HAIs),including Methicillin-resistant Staphylococcus aureus (MRSA), are becoming an international crisis. Bacterial spores such as C. diff have become an even larger problem in hospitals and in their respective communities, and it is estimated that nearly half a million Americans contract C. diff every year.
TOMI’s EPA registered BIT (Binary Ionization Technology®), branded as SteraMist, converts a low percentage hydrogen peroxide into a hydroxyl radical by passing the liquid through an atmospheric cold plasma arc, a technology initially developed under the sponsorship of the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. SteraMist BIT quickly destroys deadly viruses, bacteria and spores before they pose a threat to patients, healthcare workers and their communities.
TOMI’s SteraMist helps hospitals reduce their HAI rates by destroying the microscopic germs that may be missed during the manual cleaning process. TOMI’s germ fighting technology uses an environmentally-friendly process, the only by-product of which is oxygen and humidity. The SteraMist aerosol quickly destroys infectious germs in less than five seconds. Hospitals using SteraMist devices have reported and published outcomes in papers and in a peer-reviewed journal showing significant decreases in C. diff rooms after the use of SteraMist.
Dr. Shane further stated: “Hospitals can and should do more to keep patients safe. No one wants a loved one to go to the hospital and contract C. diff or any hospital acquired infection. Hospitals routinely using SteraMist have repeatedly demonstrated lower infection rates, which leads to enhanced patient and employee safety. Hospitals using our technology can stop the spread of infections while improving their bottom line.”
Uniquely designed for ease of use and portability, a hospital’s environmental services staff can operate SteraMist quickly without disrupting hospital operations. With a five second exposure time, the surface unit can disinfect a hospital room’s high touch surfaces and delicate medical equipment in less than 10 minutes. SteraMist is designed to go in, above, beyond, under and around objects in patient rooms, operating rooms, equipment rooms, emergency rooms, intensive care units and public areas. SteraMist does not damage medical equipment. Many hospitals in the U.S., Europe, West Africa, Central America and Asia have used SteraMist in their decontamination protocols. SteraMistis also used in skilled nursing facilities, ambulatory surgery centers, long term acute care facilities and childcare facilities.
About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing eco-friendly environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion) and is represented by the TOMI SteraMist brand of products, which produce a germ-killing aerosol that behaves like a gas.
TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.
TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association. For additional information, visit www.tomimist.com or contact us at email@example.com.
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
“The C Diff Foundation’s mission is to educate and advocate for Clostridium difficile infection prevention, treatments, support, and environmental safety worldwide.
The C Diff Foundation’s organization is comprised of 100% volunteering members who are dedicated to our mission and adhere to the Foundation’s Code of Ethics
which prohibits the endorsement and promotion of products, services, medications, or clinical studies in progress.
All website entries, public presentations, and workshops are to raise C. diff. infection awareness in all areas of the C Diff Foundation’s mission statement, including infection prevention, sepsis, healthcare-associated infections, antimicrobial resistance, antibiotic stewardship and provide education on all the above.”
In the fight against healthcare-acquired infections (HAIs), today’s healthcare facilities need proven solutions to kill a broad range of infection-causing pathogens, from deadly hospital pathogens like Clostridium difficile (C. difficile) to new threats posed by emerging viral pathogens.
To ensure its disinfectants continue to meet the highest standards of efficacy, Clorox Healthcare voluntarily tested two of its leading ready-to-use bleach disinfectants using updated U.S. Environmental Protection Agency (EPA) recommended standards, which raise the bar for sporicidal disinfectant efficacy.
February 28th, 2017 Clorox Healthcare announced that Clorox Healthcare® Bleach Germicidal Wipes and Clorox Healthcare® Bleach Germicidal Cleaners are now EPA-registered to kill C. difficile spores in three minutes, tested in the presence of a three-part organic soil load, and have gained new disinfection claims for emerging viral pathogens including SARS-associated Coronavirus (SARS-CoV), Middle East Respiratory Syndrome-associated Coronavirus (MERS-CoV) and other common causes of HAIs.
“At Clorox Healthcare, we are dedicated to safeguarding patient environments and continuously strive to ensure our surface disinfectants meet the needs of the ever-changing healthcare environment,” says Lynda Lurie, Director – Marketing, Clorox Healthcare. “We made these changes proactively so that healthcare professionals can be prepared for whatever comes through their doors, wherever care is delivered.”
The new testing standards create a higher challenge for sporicidal disinfectant efficacy. Through voluntary testing, Clorox Healthcare Bleach Germicidal disinfectants have been able to maintain, and in some cases improve, contact times, killing 99.9999 percent of C. difficile spores – the EPA’s required threshold for efficacy – within three minutes, even in the presence of the three-part organic soil load.
*PLEASE NOTE – The C Diff Foundation does not endorse any products and/or clinical study in progress. All website postings are strictly for informational purposes only.